Rengaswamy Asokan, MD
Internal Medicine · Wayne, NJNPI 1639196256
Payments from drug & device makers
Across 220 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$665
- Amarin Pharma, Inc.$481
- Novo Nordisk$458
- Lilly USA, LLC$439
- GSK$215
- Novartis$176
- plus $779 from 18 others
What the payments were for
- Food & beverage$3,15998%
- Education$532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $665 |
| Amarin Pharma, Inc. | 31 | $481 |
| Novo Nordisk | 31 | $458 |
| Lilly USA, LLC | 33 | $439 |
| GSK | 15 | $215 |
| Novartis | 12 | $176 |
| Pfizer | 10 | $159 |
| Merck | 8 | $104 |
| Exact Sciences | 5 | $91 |
| Avanir Pharmaceuticals, Inc. | 6 | $83 |
| AbbVie(2 entities) | 4 | $55 |
| Collegium Pharmaceutical, Inc. | 3 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Sientra, Inc. | 1 | $35 |
| Amgen | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Baxter Healthcare | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $16 |
| SK Life Science, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Neurelis, Inc. | 1 | $13 |
| Athena Bioscience, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$124
How this compares
$3,213 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 307 | $108,187 |
| JanuviaSitagliptin Phosphate | 64 | $61,921 |
| FarxigaDapagliflozin Propanediol | 101 | $60,138 |
| TrulicityDulaglutide | 56 | $55,729 |
| OzempicSemaglutide | 57 | $54,078 |
| VascepaIcosapent Ethyl | 97 | $41,473 |
| RybelsusSemaglutide | 22 | $27,358 |
| JardianceEmpagliflozin | 26 | $18,332 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $18,169 |
| TradjentaLinagliptin | 25 | $16,485 |
| LinzessLinaclotide | 23 | $12,402 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,339 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $9,989 |
| XareltoRivaroxaban | 13 | $9,849 |
| BrilintaTicagrelor | 24 | $9,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $159 | $108,187307 claims |
| Novo NordiskOzempic, Rybelsus | $458 | $81,43679 claims |
| MerckJanuvia, Janumet | $104 | $80,09183 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $665 | $73,036136 claims |
| Lilly USA, LLCTrulicity | $439 | $55,72956 claims |
| Boehringer IngelheimJardiance, Tradjenta | $16 | $34,81751 claims |
| GSKBreo Ellipta, Anoro Ellipta | $215 | $20,32967 claims |
| AbbVieLinzess | $55 | $12,40223 claims |
| NovartisEntresto | $176 | $7,57411 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $4,14617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Wayne
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.